Skip to content
Screener

Beam Therapeutics BEAM Comprehensive Income (Loss), Net of Tax, Attributable to Parent

Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies

Wave Life Sciences logo
Wave Life SciencesWVE
-$69.27M-37.4%
Intellia Therapeutics logo
Intellia TherapeuticsNTLA
-$107.42M-5.7%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
-$129.69M+3.0%
Prime Medicine logo
Prime MedicinePRME
-$42.12M+19.9%
Disc Medicine logo
Disc MedicineIRON
-$65.04M-92.2%
Arrowhead Research logo
Arrowhead ResearchARWR

Other financials

Income statement

See full
Revenue$31.7M+325%
Operating income-$107.2M+10.1%
Net income-$94.3M+12.9%
EPS (diluted)-$0.91+26.0%

Balance sheet

See full
Cash & equivalents$288.3M-45.4%
Total debt$250.8M+58.6%
Total equity$1.2B+3.1%
Total assets$1.5B+0.9%

Cash flow

See full
Operating cash flow-$128.5M-23.7%
CapEx$2.2M-27.2%
Free cash flow-$130.7M-22.2%

Valuation

See full
Market cap$2.84B+63.5%
Enterprise value$2.8B+74.1%
P/S17.3×-11.5×

Profitability

See full
Operating margin-226.6%-90.5pp
Net margin-742.7%
FCF margin-234%-86.6pp

Returns & leverage

See full
Return on equity-47.1%
Debt / equity0.2×+0.1×
Current ratio17×+8.2×

Where this comes from

Reported directly by Beam Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.

The source filing: Beam Therapeutics’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 7:22 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-210338
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Change in fair value of contingent consideration liabilities514(27)
Interest and other income (expense), net9,8679,864
Total other income (expense)12,89710,956
Net loss$(94,318)$(108,330)
Unrealized gain (loss) on marketable securities(2,181)(519)
Comprehensive loss$(96,499)$(108,849)
Net loss per common share, basic and diluted$(0.91)$(1.23)
Weighted-average common shares outstanding, basic and diluted103,262,00187,975,311

Item 1. Financial Statements (Unaudited)

FAQ

What is Beam Therapeutics's comprehensive income (loss), net of tax, attributable to parent?
Beam Therapeutics (BEAM) reported comprehensive income (loss), net of tax, attributable to parent of -$96.5M in Q1 2026.
How has Beam Therapeutics's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
Beam Therapeutics's comprehensive income (loss), net of tax, attributable to parent increased by 11.3% year-over-year, from -$108.85M to -$96.5M.
What is the long-term trend for Beam Therapeutics's comprehensive income (loss), net of tax, attributable to parent?
Over 2 years (2021 to 2024), Beam Therapeutics's comprehensive income (loss), net of tax, attributable to parent has grown at a 0.8% compound annual growth rate (CAGR), from -$370.68M to -$376.67M.
What does comprehensive income (loss), net of tax, attributable to parent mean?
This metric represents the total change in equity from non-owner sources, including net income and other comprehensive income items such as foreign currency translation adjustments or unrealized gains on securities. It provides a more holistic view of the company's financial performance beyond traditional net income by capturing broader economic impacts. Investors use this to evaluate the total change in the company's net worth during a reporting period.

Ask your AI about Beam Therapeutics's comprehensive income (loss), net of tax, attributable to parent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude